Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings
Authors:
- Siddharth MookerjeeSMSiddharth Mookerjee
- Edward J. MillsEMEdward J. Mills
- Andrew BoulleABAndrew Boulle
- Nathan FordNFNathan Ford
- 15 May 2012
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 26 (8) , 929-938
Abstract
A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure.Keywords
This publication has 36 references indexed in Scilit:
- HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational studyThe Lancet Infectious Diseases, 2011
- Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited SettingJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Driving a decade of change: HIV/AIDS, patents and access to medicines for allJournal of the International AIDS Society, 2011
- High efficacy of lopinavir/r‐based second‐line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, CambodiaJournal of the International AIDS Society, 2011
- Pooling Strategies to Reduce the Cost of HIV-1 RNA Load Monitoring in a Resource-Limited SettingClinical Infectious Diseases, 2010
- Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South AfricaAIDS, 2010
- Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-EffectivenessJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Mortality after failure of antiretroviral therapy in sub‐Saharan AfricaTropical Medicine & International Health, 2010
- Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in MalawiThe Lancet, 2008
- Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and FacilitatorsPLOS Medicine, 2006